Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Helus PharmaHELP +0.93%22 3-Year EBITDA Growth Rate is 19.20% as of Jun. 2026, which is at its 10-year median of 19.20. GuruFocus rates HELP with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,124 Biotechnology companies, Helus Pharma ranks better than 55.07% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Helus Pharma was 20.80% per year. The lowest was 8.00% per year. And the median was 19.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Helus Pharma 3-Year EBITDA Growth Rate Related Terms
HELP vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Helus Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helus Pharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helus Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Helus Pharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.20% mean?
Helus Pharma (HELP) has a 3-Year EBITDA Growth Rate of 19.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Helus Pharma and its competitors. This is near median its historical median of 19.20. Over the past decade, Helus Pharma's 3-Year EBITDA Growth Rate has ranged from 8.00 to 20.80. According to the industry distribution chart, Helus Pharma ranks #505 out of 1124 companies in the Biotechnology industry, placing it in the top 44.9%.
Is Helus Pharma's 3-Year EBITDA Growth Rate too high?
Helus Pharma's current 3-Year EBITDA Growth Rate of 19.20% is near median its 10-year median of 19.20. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 20.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.65. Helus Pharma's value of 19.20% is 31.1% above this industry median. Based on the distribution chart, Helus Pharma ranks #505 out of 1124 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Helus Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helus Pharma ranks #505 out of 1124 companies for 3-Year EBITDA Growth Rate. This puts Helus Pharma in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.65. Helus Pharma's value of 19.20% is 31.1% above this benchmark. Historically, Helus Pharma's own 3-Year EBITDA Growth Rate has ranged from 8.00 to 20.80 over the past decade. While the company's 10-year median is 19.20 vs. the industry median of 14.65, Helus Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,124 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Helus Pharma's current 3-Year EBITDA Growth Rate of 19.20% is 31.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Helus Pharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helus Pharma's current 3-Year EBITDA Growth Rate is 19.20%, which is near median its own 10-year median of 19.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current 3-Year EBITDA Growth Rate of 19.20%. The current 3-Year EBITDA Growth Rate is 19.20%, which is near median its 10-year median of 19.20 and 31.1% above the Biotechnology industry median of 14.65. Helus Pharma's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Helus Pharma (HELP), the current 3-Year EBITDA Growth Rate is 19.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
22GF Score
Get the complete analysis for HELP
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HELP has been successfully added to your 
